Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT01155258. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with vinorelbine ditartrate may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.
Study identification
- NCT ID
- NCT01155258
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 19 participants
Conditions and interventions
Conditions
- Extensive Stage Small Cell Lung Cancer
- Hereditary Paraganglioma
- Male Breast Cancer
- Malignant Paraganglioma
- Metastatic Gastrointestinal Carcinoid Tumor
- Metastatic Pheochromocytoma
- Pancreatic Polypeptide Tumor
- Recurrent Breast Cancer
- Recurrent Cervical Cancer
- Recurrent Endometrial Carcinoma
- Recurrent Gastrointestinal Carcinoid Tumor
- Recurrent Islet Cell Carcinoma
- Recurrent Neuroendocrine Carcinoma of the Skin
- Recurrent Non-small Cell Lung Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Ovarian Germ Cell Tumor
- Recurrent Pheochromocytoma
- Recurrent Prostate Cancer
- Recurrent Renal Cell Cancer
- Recurrent Small Cell Lung Cancer
- Recurrent Uterine Sarcoma
- Regional Gastrointestinal Carcinoid Tumor
- Regional Pheochromocytoma
- Stage III Cervical Cancer
- Stage III Endometrial Carcinoma
- Stage III Neuroendocrine Carcinoma of the Skin
- Stage III Ovarian Epithelial Cancer
- Stage III Ovarian Germ Cell Tumor
- Stage III Prostate Cancer
- Stage III Renal Cell Cancer
- Stage III Uterine Sarcoma
- Stage IIIA Breast Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Breast Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Stage IV Endometrial Carcinoma
- Stage IV Neuroendocrine Carcinoma of the Skin
- Stage IV Non-small Cell Lung Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Ovarian Germ Cell Tumor
- Stage IV Prostate Cancer
- Stage IV Renal Cell Cancer
- Stage IV Uterine Sarcoma
- Stage IVA Cervical Cancer
- Stage IVB Cervical Cancer
- Thyroid Gland Medullary Carcinoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2010
- Primary completion
- Dec 31, 2012
- Completion
- Apr 30, 2014
- Last update posted
- Jun 12, 2016
2010 – 2014
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01155258, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2016 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01155258 live on ClinicalTrials.gov.